Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 2 , Pages 178-183 , June 2009

Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer

  • Hacer Cesur, MS

      Affiliations

    • Department of Bioengineering, University of Illinois at Chicago, Chicago, Illinois, USA
    • ,
  • Israel Rubinstein, MD

      Affiliations

    • Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago, Illinois, USA
    • Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
    • Jesse Brown VA Medical Center, Chicago, Illinois, USA
    • ,
  • Ashwini Pai, PhD

      Affiliations

    • Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago, Illinois, USA
    • ,
  • Hayat Önyüksel, PhD

      Affiliations

    • Department of Bioengineering, University of Illinois at Chicago, Chicago, Illinois, USA
    • Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago, Illinois, USA
    • Corresponding Author InformationCorresponding author. Department of Biopharmaceutical Sciences (M/C 865), College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612-7231, USA.

Received 31 December 2007 ,Accepted 1 September 2008.

References 

  1. Ashok B, Arleth L, Hjelm RP, Rubinstein I, Önyüksel H. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation. J Pharm Sci. 2004;93:2476–2487
  2. Krishnadas A, Rubinstein I, Önyüksel H. Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs. Pharm Res. 2003;20:297–302
  3. Önyüksel H, Ikezaki H, Patel M, Gao XP, Rubinstein I. A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo. Pharm Res. 1999;16:155–160
  4. Koo OM, Rubinstein I, Önyüksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine. 2005;1:193–212
  5. Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev. 2004;56:1273–1289
  6. Lukyanov AN, Gao Z, Mazzola L, Torchilin VP. Polyethylene glycol-diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice. Pharm Res. 2002;19:1424–1429
  7. Koo OM, Rubinstein I, Önyüksel H. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine. Nanomedicine. 2005;1:77–84
  8. Hammad MA, Muller BW. Solubility and stability of lorazepam in bile salt/soya phosphatidylcholine-mixed micelles. Drug Dev Ind Pharm. 1999;25:409–417
  9. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid–PEG conjugates. Adv Drug Deliv Rev. 2004;56:1177–1192
  10. Owa T, Yoshino H, Okauchi T, Yoshimatsu K, Ozawa Y, Sugi NH, et al. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem. 1999;42:3789–3799
  11. Yamada Y, Yamamoto N, Shimoyama T, Horiike A, Fujisaka Y, Takayama K, et al. Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. Cancer Sci. 2005;96:721–728
  12. Ozawa Y, Sugi NH, Nagasu T, Owa T, Watanabe T, Koyanagi N, et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer. 2001;37:2275–2282
  13. Smyth J, Aamdal S, Awada A, Dittrich C, Caponigro F, Schoffski P, et al. Phase II study of E7070 in patients with metastatic melanoma. Ann Oncol. 2005;16:158–161
  14. Fukuoka K, Usuda J, Iwamoto Y, Fukumoto H, Nakamura T, Yoneda T, et al. Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest New Drugs. 2001;19:219–227
  15. Abbate F, Casini A, Owa T, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett. 2004;14:217–223
  16. Tripathy D. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. Oncologist. 2007;12:375
  17. Dittrich C, Zandvliet AS, Gneist M, Huitema AD, King AA, Wanders J. A phase I and pharmacokinetic study of indisulam in combination with carboplatin. Br J Cancer. 2007;96:559–566
  18. Nakatsu N, Yoshida Y, Yamazaki K, Nakamura T, Dan S, Fukui Y, et al. Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Mol Cancer Ther. 2005;4:399–412
  19. Raymond E, ten Bokkel Huinink WW, Taieb J, Beijnen J, Faivre S, Wanders J, et al. Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. J Clin Oncol. 2002;20:3508
  20. Yokoi A, Kuromitsu J, Kawai T, Nagasu T, Sugi NH, Yoshimatsu K, et al. Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis. Mol Cancer Ther. 2002;1:275–286
  21. Punt C, Fumoleau P, van de Walle B, Faber M, Ravic M, Campone M. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC–Early Clinical Studies Group (ECSG). Ann Oncol. 2001;12:1289–1293
  22. Zandvliet AS, Copalu W, Schellens JH, Beijnen JH, Huitema AD. Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes. Drug Metab Dispos. 2006;34:1041–1046
  23. Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH. Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods. 1997;208:151–158
  24. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1:1112–1116
  25. Lim SB, Rubinstein I, Önyüksel H. Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomiclles. Int J Pharm. 2008;356:345–350
  26. Zhang JX, Hansen CB, Allen TM, Boey A, Boch R. Lipid-derivatized poly (ethylene glycol) micellar formulations of benzoporphyrin derivatives. J Control Release. 2003;86:323–338
  27. Hauss JD. In: Oral lipid-based formulations: enhancing the bioavailability of poorly water-soluble drugs (drugs and the pharmaceutical sciences). 170:New York: Informa Healthcare; 2007;p. 158–168

 This work was supported, in part, by Eisai Inc., National Institutes of Health grants RO1 CA121797, AGC24026-01 and C06RR15482, VA Merit Review, and Department of Defense contract W81XWH-07-1-0445.

PII: S1549-9634(08)00147-0

doi: 10.1016/j.nano.2008.09.001

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 2 , Pages 178-183 , June 2009

Article Tools

* Image Usage & Resolution